Načítá se...
Phase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301
LESSONS LEARNED. Weekly nanoparticle albumin‐bound‐paclitaxel (75 mg/m(2)) in combination with carboplatin (area under the curve 6 mg/mL/min) in elderly patients with previously untreated, advanced non‐small cell lung cancer showed favorable efficacy, was well tolerated, and showed less neuropathic...
Uloženo v:
Vydáno v: | Oncologist |
---|---|
Hlavní autoři: | , , , , , , , , , , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
AlphaMed Press
2017
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5469596/ https://ncbi.nlm.nih.gov/pubmed/28526722 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0059 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|